ReviewFrontiers in pharmacology2026
Evolution of artificial intelligence and machine learning in DILI toxicogenomics: from descriptive profiling to mechanistic insights.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug-induced liver injury (DILI) is a critical safety issue in drug development, characterized by its idiosyncratic nature, complex mechanisms, and poor predictability in standard preclinical models. High-dimensional omics strategies, particularly toxicogenomics, have attracted increased interest in addressing the complexity of hepatotoxicity, especially in the context of emerging artificial intelligence (AI) technologies. This review traces the evolution of AI and machine learning (ML) within DILI-related omics research, highlighting toxicogenomics as a primary driver of advancement in this field. We first explore the early studies in computational toxicogenomics, which primarily focused on exploratory approaches, utilizing clustering, time-series, co-expression, and basic pathway analyses to identify molecular signatures indicative of nascent liver injury. We then examine how the adoption of supervised machine learning enabled robust predictive modeling, facilitating systematic feature selection, signature refinement, and rigorous validation. More recently, the field has been further transformed by deep learning, biologically informed network architectures, and generative artificial intelligence. Across these methodological eras, AI has enhanced mechanistic interpretation by identifying biologically relevant signatures, integrating multimodal evidence, and strengthening evidence for established DILI mechanisms, including oxidative stress, mitochondrial dysfunction, altered xenobiotic metabolism, inflammation, and cell death. Ultimately, the synergy of AI and DILI toxicogenomics has transitioned the discipline from descriptive profiling toward mechanism-driven predictive toxicology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.